Are higher doses of proton pump inhibitors better in acute peptic bleeding?

Medwave. 2016 Jun 24:16 Suppl 2:e6476. doi: 10.5867/medwave.2016.6476.
[Article in English, Spanish]

Abstract

Although there is broad consensus about the benefits of proton pump inhibitors in acute upper peptic bleeding, there is still controversy over their optimal dosing. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified six systematic reviews including 27 randomized trials addressing this question. We combined the evidence using meta-analysis and generated a summary of findings table following the GRADE approach. We concluded high-dose proton pump inhibitors probably result in little or no difference in re-bleeding rate or mortality. The risk/benefit and cost/benefit balance probably favor use of low-doses.

Si bien existe consenso acerca de la utilidad de los inhibidores de la bomba de protones en la hemorragia digestiva péptica aguda, persiste la controversia sobre cuál es la dosis óptima. Utilizando la base de datos Epistemonikos, la cual es mantenida mediante búsquedas en 30 bases de datos, identificamos seis revisiones sistemáticas que en conjunto incluyen 27 estudios aleatorizados evaluando esta pregunta. Realizamos un metanálisis y tablas de resumen de los resultados utilizando el método GRADE. Concluimos que las dosis altas de inhibidores de la bomba de protones probablemente resultan en poca o nula diferencia en el riesgo de resangrado y mortalidad. El balance riesgo/beneficio y costo/beneficio son probablemente desfavorables a la utilización de dosis altas.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Acute Disease
  • Cost-Benefit Analysis
  • Dose-Response Relationship, Drug
  • Humans
  • Peptic Ulcer Hemorrhage / drug therapy*
  • Peptic Ulcer Hemorrhage / pathology
  • Proton Pump Inhibitors / administration & dosage*
  • Proton Pump Inhibitors / adverse effects
  • Proton Pump Inhibitors / economics
  • Randomized Controlled Trials as Topic
  • Recurrence

Substances

  • Proton Pump Inhibitors